Skip to main content

COX-2 Inhibitors Tackle Cancer

Image: Courtesy of Hibiki Kawamata, Smith College A drug developer's dream, rationally designed to quell inflammation, COX-2 inhibitors are also prime candidates for preventing cancer or its recurrence. Gary J. Kelloff, chief of the chemoprevention branch at the National Cancer Institute (NCI), lists the requirements for a molecular target such as the COX-2 enzyme: It must be highly expressed in precancer or cancer cells and not in others; blocking it isn't toxic and doesn't disrupt normal func

Written byRicki Lewis
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00

A drug developer's dream, rationally designed to quell inflammation, COX-2 inhibitors are also prime candidates for preventing cancer or its recurrence. Gary J. Kelloff, chief of the chemoprevention branch at the National Cancer Institute (NCI), lists the requirements for a molecular target such as the COX-2 enzyme: It must be highly expressed in precancer or cancer cells and not in others; blocking it isn't toxic and doesn't disrupt normal function; effects must be measurable; and there must be clinical benefit. "COX-2 is an ideal target," he says.

The COX-2 inhibitors shot to pharmaceutical fame in December 1998, when the Food and Drug Administration approved Celebrex (celecoxib) to treat osteoarthritis and rheumatoid arthritis. Five months later Vioxx (rofecoxib) followed, approved for osteoarthritis, acute pain, and dysmenorrhea.1 But the use for cancer--begun with the 1999 approval of Celebrex to treat a type of colon cancer, familial adenomatous polyposis (FAP)--fits right into NCI's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo
Optimizing Critical Steps in T-Cell Engineering

Optimizing Critical Steps in T-Cell Engineering

Fujifilm

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen